| Year |
Title |
Altmetric |
| 2023
|
Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19.
Journal of Clinical Medicine.
12:552-552.
2023
|
|
| 2022
|
Changes in Plasma Levels of ADAMTS13 and von Willebrand Factor in Patients Undergoing Elective Joint Arthroplasty.
Journal of Clinical Medicine.
11.
2022
|
|
| 2022
|
Protein arginine methyltransferase 1 in the generation of immune megakaryocytes: A perspective review.
Journal of Biological Chemistry.
298.
2022
|
|
| 2022
|
ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
20:2197-2203.
2022
|
|
| 2022
|
ADAMTS13 protease or lack of von Willebrand factor protects irradiation and melanoma-induced thrombotic microangiopathy in zebrafish.
Journal of Thrombosis and Haemostasis.
20:2270-2283.
2022
|
|
| 2022
|
Race, rituximab, and relapse in TTP.
Blood.
140:1335-1344.
2022
|
|
| 2022
|
Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura.
Thrombosis and Haemostasis.
122:344-352.
2022
|
|
| 2022
|
A Simple, Robust, and Cost-effective Method for Genotyping Small-scale Mutations.
2022
|
|
| 2022
|
Animal models for thrombotic thrombocytopenic purpura: a narrative review
2022
|
|
| 2021
|
A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
19:1888-1895.
2021
|
|
| 2021
|
Low ADAMTS-13 predicts adverse outcomes in hospitalized patients with suspected heparin-induced thrombocytopenia.
Research and Practice in Thrombosis and Haemostasis.
5.
2021
|
|
| 2021
|
The standard of care for immune thrombotic thrombocytopenic purpura today.
Journal of Thrombosis and Haemostasis.
19:1864-1871.
2021
|
|
| 2021
|
Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
Thrombosis and Haemostasis.
121:506-517.
2021
|
|
| 2021
|
Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
19:370-379.
2021
|
|
| 2021
|
Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality..
Th Open: Companion Journal to Thrombosis and Haemostasis.
5:e1-e7.
2021
|
|
| 2021
|
How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
2021
|
|
| 2021
|
Identification of Biomarkers in Patients with Thrombotic Thrombocytopenic Purpura Presenting with Large and Small Ischemic Stroke.
Cerebrovascular Diseases Extra.
11:29-36.
2021
|
|
| 2020
|
Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.
Blood Advances.
4:5378-5388.
2020
|
|
| 2020
|
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
18:2503-2512.
2020
|
|
| 2020
|
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
18:2486-2495.
2020
|
|
| 2020
|
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
18:2496-2502.
2020
|
|
| 2020
|
Factor VIII binding affects the mechanical unraveling of the A2 domain of von Willebrand factor.
Journal of Thrombosis and Haemostasis.
18:2169-2176.
2020
|
|
| 2020
|
Exclusive use of PowerFlow ports may not be appropriate for all patients.
Journal of Clinical Apheresis.
35:66-68.
2020
|
|
| 2020
|
Histone-induced thrombotic thrombocytopenic purpura in adamts13-/- zebrafish depends on von Willebrand factor.
The hematology journal : the official journal of the European Haematology Association / EHA.
105:1107-1119.
2020
|
|
| 2019
|
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
Blood Advances.
3:4177-4186.
2019
|
|
| 2019
|
Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.
Journal of Thrombosis and Haemostasis.
17:2099-2109.
2019
|
|
| 2019
|
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Blood.
134:1095-1105.
2019
|
|
| 2019
|
Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols.
Journal of Thrombosis and Haemostasis.
17:596-606.
2019
|
|
| 2019
|
Validation and cost-effectiveness of an in-house dithiothreitol (DTT)treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals.
Transfusion and Apheresis Science.
58:152-155.
2019
|
|
| 2019
|
Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury.
Journal of Neurotrauma.
36:222-229.
2019
|
|
| 2019
|
Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial Shear.
Thrombosis and Haemostasis.
119:1933-1946.
2019
|
|
| 2019
|
Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
The hematology journal : the official journal of the European Haematology Association / EHA.
104:166-175.
2019
|
|
| 2018
|
Understanding thrombotic microangiopathies in children.
Intensive Care Medicine.
44:1536-1538.
2018
|
|
| 2018
|
Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma.
Thrombosis and Haemostasis.
118:676-687.
2018
|
|
| 2018
|
Transfusion of platelets loaded with recombinant ADAMTS13 (A disintegrin and metalloprotease with thrombospondin type 1 repeats-13) is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura
2018
|
|
| 2017
|
ADAMTS13 test and/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis.
Transfusion.
57:2609-2618.
2017
|
|
| 2017
|
Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.
Annals of Hematology.
96:1849-1855.
2017
|
|
| 2017
|
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
Journal of Thrombosis and Haemostasis.
15:1889-1900.
2017
|
|
| 2017
|
Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development
2017
|
|
| 2017
|
Mutations in Coagulation Factor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma..
Th Open: Companion Journal to Thrombosis and Haemostasis.
1:e113-e121.
2017
|
|
| 2017
|
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation.
Blood.
129:1184-1196.
2017
|
|
| 2017
|
Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: comment.
Journal of Thrombosis and Haemostasis.
15:586-589.
2017
|
|
| 2017
|
Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Journal of Thrombosis and Haemostasis.
15:110-121.
2017
|
|
| 2017
|
Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.
Thrombosis and Haemostasis.
117:691-699.
2017
|
|
| 2016
|
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura..
Blood Advances.
1:75-83.
2016
|
|
| 2016
|
Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A.
Haemophilia.
22:e565-e567.
2016
|
|
| 2016
|
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
The hematology journal : the official journal of the European Haematology Association / EHA.
101:1319-1326.
2016
|
|
| 2016
|
Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: A potential link of inflammation to TTP.
Blood.
128:110-119.
2016
|
|
| 2016
|
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
Transfusion.
56:1763-1774.
2016
|
|
| 2016
|
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.
Transfusion.
56:1775-1785.
2016
|
|
| 2016
|
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model..
Transfusion.
2016
|
|
| 2016
|
Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.
Blood.
127:464-472.
2016
|
|
| 2016
|
Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP.
Blood.
blood-2015.
2016
|
|
| 2016
|
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura
2016
|
|
| 2015
|
High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome
2015
|
|
| 2015
|
ADAMTS13 and von Willebrand factor interactions.
Current Opinion in Hematology.
22:452-459.
2015
|
|
| 2015
|
Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease.
Journal of Thrombosis and Haemostasis.
13:1064-1072.
2015
|
|
| 2015
|
ADAMTS13, lucky to have a hydrophobic pocket.
Blood.
125:1852-1853.
2015
|
|
| 2015
|
ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2.
Cellular and Molecular Life Sciences.
72:349-356.
2015
|
|
| 2015
|
ADAMTS13 and von willebrand factor in thrombotic thrombocytopenic purpura.
Annual Review of Medicine.
66:211-225.
2015
|
|
| 2015
|
Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.
Circulation.
131:1202-1213.
2015
|
|
| 2015
|
Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models.
Blood.
125:3326-3334.
2015
|
|
| 2014
|
Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis.
Blood.
124:3799-3807.
2014
|
|
| 2014
|
Research advances on ADAM28 expression and ADAM28-mediated tumor metastasis.
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology.
22:1142-1147.
2014
|
|
| 2014
|
Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von willebrand factor string formation under flow in a free-thiol-dependent manner
2014
|
|
| 2014
|
DNase, ADAMTS13, and iPAD4: Good for the heart.
Blood.
123:10-11.
2014
|
|
| 2014
|
Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.
The hematology journal : the official journal of the European Haematology Association / EHA.
99.
2014
|
|
| 2014
|
Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura..
Hereditary Genetics.
3.
2014
|
|
| 2013
|
Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway.
Leukemia Research.
37:1719-1725.
2013
|
|
| 2013
|
Compromised shear-dependent cleavage of type 2N von willebrand factor variants by ADAMTS13 in the presence of factor VIII.
Thrombosis and Haemostasis.
110:202-204.
2013
|
|
| 2013
|
Structure-function and regulation of ADAMTS-13 protease.
Journal of Thrombosis and Haemostasis.
11:11-23.
2013
|
|
| 2013
|
Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: A report from the Southern Network on Adverse Reactions (SONAR).
British Journal of Haematology.
161:896-898.
2013
|
|
| 2013
|
AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.
Blood.
121:3825-3829.
2013
|
|
| 2013
|
ADAMTS13, TTP and Beyond..
Hereditary Genetics.
2:e104.
2013
|
|
| 2013
|
Biochemistry and physiological functions of ADAMTS7 metalloprotease..
Advances in biochemistry.
1.
2013
|
|
| 2012
|
Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.
Blood.
120:4134-4142.
2012
|
|
| 2012
|
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: A 20-year review from the southern network on adverse reactions (SONAR).
Seminars in vascular medicine.
38:845-853.
2012
|
|
| 2012
|
Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
Journal of Biological Chemistry.
287:32459-32466.
2012
|
|
| 2012
|
Genetic ablation of adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model
2012
|
|
| 2012
|
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
Blood.
119:5294-5300.
2012
|
|
| 2012
|
ADAMTS13 meets MR, then what?.
Blood.
119:3652-3654.
2012
|
|
| 2012
|
Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Blood.
119:3836-3843.
2012
|
|
| 2011
|
Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.
Thrombosis and Haemostasis.
106:947-958.
2011
|
|
| 2011
|
Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis
2011
|
|
| 2011
|
A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura.
Transfusion.
51:1580-1591.
2011
|
|
| 2011
|
Analysis of morphology of platelet aggregates formed on collagen under laminar blood flow.
Journal of bioengineering.
39:922-929.
2011
|
|
| 2011
|
Toward a definition of "fresh" whole blood: An in vitro characterization of coagulation properties in refrigerated whole blood for transfusion.
Transfusion.
51:43-51.
2011
|
|
| 2010
|
Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress.
Journal of Biological Chemistry.
285:28596-28603.
2010
|
|
| 2010
|
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
The hematology journal : the official journal of the European Haematology Association / EHA.
95:1555-1562.
2010
|
|
| 2010
|
Amino acid residues Arg659, Arg660, and Tyr 661 in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.
Blood.
115:2300-2310.
2010
|
|
| 2010
|
ADAMTS13 testing: Why bother?.
Blood.
115:1475-1476.
2010
|
|
| 2010
|
A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection.
Transfusion.
50:208-212.
2010
|
|
| 2009
|
Von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size.
Journal of Thrombosis and Haemostasis.
7:1749-1752.
2009
|
|
| 2009
|
Thromboelastography of patients after fontan compared with healthy children.
Pediatric Cardiology.
30:771-776.
2009
|
|
| 2009
|
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.
Blood.
113:2172-2180.
2009
|
|
| 2009
|
Enteropeptidase, a type II transmembrane serine protease.
Frontiers in Bioscience (Elite Edition).
1 E:242-249.
2009
|
|
| 2009
|
A team player: The disintegrin domain of ADAMTS13.
Blood.
113:5373-5374.
2009
|
|
| 2009
|
Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.
Molecular Therapy.
17:34-41.
2009
|
|
| 2009
|
Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
Journal of Thrombosis and Haemostasis.
7:80-86.
2009
|
|
| 2009
|
Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.
Blood.
114:1666-1674.
2009
|
|
| 2009
|
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): Review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Kidney International.
75.
2009
|
|
| 2008
|
Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells.
Journal of Thrombosis and Haemostasis.
6:1233-1235.
2008
|
|
| 2008
|
Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13
2008
|
|
| 2007
|
Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura. A Report From the SERF-TTP Research Group and the RADAR Project.
Journal of the American College of Cardiology.
50:1138-1143.
2007
|
|
| 2007
|
The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow.
Blood.
110:1887-1894.
2007
|
|
| 2006
|
Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts.
Blood.
108:2207-2215.
2006
|
|
| 2006
|
Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
Journal of Thrombosis and Haemostasis.
4:1707-1717.
2006
|
|
| 2006
|
An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura.
Journal of Thrombosis and Haemostasis.
4:1162-1164.
2006
|
|
| 2006
|
Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo.
Journal of Thrombosis and Haemostasis.
4:1063-1070.
2006
|
|
| 2005
|
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Seminars in vascular medicine.
31:659-672.
2005
|
|
| 2005
|
The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.
Journal of Biological Chemistry.
280:29428-29434.
2005
|
|
| 2004
|
Binding of platelet glycoprotein Ibα to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13
2004
|
|
| 2004
|
Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.
Blood.
103:4043-4049.
2004
|
|
| 2003
|
Cleavage of the ADAMTS13 Propeptide Is Not Required for Protease Activity.
Journal of Biological Chemistry.
278:46643-46648.
2003
|
|
| 2003
|
Structure and Function of ADATMS13, a metalloprotease that regulates thrombosis.
Nihon Kessen Shiketsu Gakkai shi = Japanese journal of thrombosis and hemostasis.
14.
2003
|
|
| 2003
|
Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
Journal of Biological Chemistry.
278:30136-30141.
2003
|
|
| 2003
|
Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
ACP journal club.
138:105-108.
2003
|
|
| 2002
|
Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells.
Journal of Biological Chemistry.
277:6858-6863.
2002
|
|
| 2002
|
ADAMTS13 and TTP.
Current Opinion in Hematology.
9:389-394.
2002
|
|
| 2001
|
Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura.
Journal of Biological Chemistry.
276:41059-41063.
2001
|
|
| 1999
|
Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide.
Journal of Molecular Biology.
292:361-373.
1999
|
|
| 1999
|
Differential activity of diethylstilbestrol versus estradiol as neonatal endocrine disruptors in the female hamster (Mesocricetus auratus) reproductive tract.
Biology of Reproduction.
61:91-100.
1999
|
|
| 1999
|
Apical sorting of bovine enteropeptidase does not involve detergent- resistant association with sphingolipid-cholesterol rafts.
Journal of Biological Chemistry.
274:1596-1605.
1999
|
|
| 1998
|
Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice
1998
|
|
| 1998
|
Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.
Journal of Biological Chemistry.
273:12135-12139.
1998
|
|
| 1998
|
Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development..
American Journal of Physiology.
274:G342-G349.
1998
|
|
| 1998
|
Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development
1998
|
|
| 1997
|
Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain.
Journal of Biological Chemistry.
272:31293-31300.
1997
|
|
| 1997
|
Endometrial hyperplasia and apoptosis following neonatal diethylstilbestrol exposure and subsequent estrogen stimulation in both host and transplanted hamster uteri.
Cancer Research.
57:1903-1908.
1997
|
|
| 1997
|
Neonatal diethylstilbestrol treatment alters the estrogen-regulated expression of both cell proliferation and apoptosis-related proto-oncogenes (c-jun, c-fos, c-myc, bax, bcl-2, and bcl-x) in the hamster uterus.
Molecular Cancer Research.
8:425-434.
1997
|
|
| 1996
|
Effect of protein C inhibitor (PCI) on in vitro fertilization.
Immunopharmacology.
33:140-142.
1996
|
|
| 1996
|
Protein C inhibitor (PCI).
Immunopharmacology.
32:53-56.
1996
|
|
| 1994
|
Inhibition of acrosin by protein C inhibitor and localization of protein C inhibitor to spermatozoa..
American Journal of Physiology.
267:C466-C472.
1994
|
|
| 1994
|
Effect of protein C inhibitor (PCI) on in vitro fertilization.
Fibrinolysis and Proteolysis.
8:145.
1994
|
|
| 1994
|
Inhibition of acrosin by protein C inhibitor and localization of protein C inhibitor to spermatozoa
1994
|
|
| 1994
|
Inhibition of acrosin by protein C inhibitor and localization of protein C inhibitor to spermatozoa
1994
|
|
| 1994
|
Serine protease inhibitors (serpins) in human seminal plasma: Concentrations and inhibition of acrosin.
Fibrinolysis and Proteolysis.
8:364-371.
1994
|
|
| |
ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2.
|
|
| |
ADAMTS13 and von Willebrand factor interactions..
Current Opinion in Hematology.
|
|
| |
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro..
Transfusion.
|
|
| |
Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A.
|
|
| |
High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
|
|
| |
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
|
|
